For US Healthcare Professionals Only
Prescribing information
Open menuMenu

Protect against rising
uric acid levels
in high-risk adult patients

A head-to-head trial vs allopurinol demonstrated superior efficacy in maintaining normal uric acid levels1

Proportion of patients with normal uric acid levels ≤7.5 mg/dL from Day 3 to Day 7 after initiating antihyperuricemic treatment (primary endpoint)1
Percentage of adult patients with uric acid levels (≤7.5 mg/dL) from day 3 to day 7 after initiating antihyperuricemic treatment: 87% with ELITEK (n=92); 78% with ELITEK and allopurinol (n=92) (P=0.001); 66% with allopurinol (n=91) (P=0.06).

Percentage of adult patients with uric acid levels (≤7.5 mg/dL) from day 3 to day 7 after initiating antihyperuricemic treatment: 87% with ELITEK (n=92); 78% with ELITEK and allopurinol (n=92) (P=0.001); 66% with allopurinol (n=91) (P=0.06).

Unlike allopurinol, ELITEK maintained normal uric acid levels in 100% of assessable adult patients2

Documented failure rate in hyperuricemic and nonhyperuricemic adult patients2
Clinical Study Data. ELITEK 0% failure rate vs allopurinol

Clinical Study Data ELITEK vs allopurinol

  • The ELITEK, ELITEK + allopurinol, and allopurinol arms had 13%, 15%, and 19% missing uric acid samples, respectively. The uric acid failure status in those patients is unknown2
Green background

No adult patients receiving ELITEK alone required antihyperuricemic treatment past 5 days2

See the full context of ELITEK efficacy and safety

Read the Clinician's Guide for an in-depth overview of ELITEK clinical data

DOWNLOAD NOW

SEE ADULT STUDY DESIGN

VIEW SAFETY PROFILE

VIEW SAFETY PROFILE

EXPLORE ELITEK MOA

CLL=chronic lymphocytic leukemia; DLBCL=diffuse large B-cell lymphoma; SLL=small lymphocytic lymphoma.

References: 1. Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone—results of a multicenter phase III study. J Clin Oncol. 2010;28(27):4207-4213. 2. ELITEK [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC. 3. Data on file. Bridgewater, NJ: sanofi-aventis U.S. LLC. 4. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844-1854. 5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. V.3.2022. ©National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed August 26, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

INDICATION

ELITEK is indicated for the initial management of plasma uric acid levels in patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. ELITEK is indicated only for a single course of treatment.

IMPORTANT SAFETY INFORMATION

WARNING: HYPERSENSITIVITY REACTIONS, HEMOLYSIS, METHEMOGLOBINEMIA, AND INTERFERENCE WITH URIC ACID MEASUREMENTS

  • Hypersensitivity Reactions: ELITEK can cause serious and fatal hypersensitivity reactions including anaphylaxis. Immediately and permanently discontinue ELITEK in patients who experience a serious hypersensitivity reaction.
  • Hemolysis: Do not administer ELITEK to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Immediately and permanently discontinue ELITEK in patients developing hemolysis. Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting ELITEK.
  • Methemoglobinemia: ELITEK can result in methemoglobinemia in some patients. Immediately and permanently discontinue ELITEK in patients developing methemoglobinemia.
  • Interference with Uric Acid Measurements: ELITEK enzymatically degrades uric acid in blood samples left at room temperature. Collect blood samples in prechilled tubes containing heparin and immediately immerse and maintain sample in an ice water bath. Assay plasma samples within 4 hours of collection.

CONTRAINDICATIONS

ELITEK is contraindicated in patients with a history of anaphylaxis or severe hypersensitivity to rasburicase or in patients with development of hemolytic reactions or methemoglobinemia with rasburicase. ELITEK is contraindicated in individuals deficient in glucose-6-phosphate dehydrogenase (G6PD).

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥20%), when used concomitantly with anticancer therapy, are vomiting, nausea, fever, peripheral edema, anxiety, headache, abdominal pain, constipation, diarrhea, hypophosphatemia, pharyngolaryngeal pain, and increased alanine aminotransferase.

USE IN SPECIFIC POPULATIONS
  • Pregnancy: Consider the benefits and risks of ELITEK and possible risks to the fetus when prescribing ELITEK to a pregnant woman
  • Lactation: Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with ELITEK and for 2 weeks after the last dose

Please see full Prescribing Information, including Boxed WARNING.

MAT-US-2020411-v2.0-08/2022
Last Updated: August 2022-08-01YYYY